Actinium Pharmaceuticals Inc Cash Flow Conversion Efficiency
Actinium Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Actinium Pharmaceuticals Inc (ATNM) has a cash flow conversion efficiency ratio of -2.548x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.87 Million) by net assets ($2.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Actinium Pharmaceuticals Inc (2006–2025)
Cash flow conversion efficiency of Actinium Pharmaceuticals Inc from 2006 to 2025. This chart illustrates how Actinium Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Actinium Pharmaceuticals Inc stock price for real-time trading data and today's change.
Actinium Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
Actinium Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Actinium Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Actinium Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Actinium Pharmaceuticals Inc (ATNM) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pacgold Ltd
AU:PGO
|
-0.032x |
|
Brand 24 SA
WAR:B24
|
0.338x |
|
SK D&D Co Ltd
KO:210980
|
-0.443x |
|
Revoil S.A
AT:REVOIL
|
-0.040x |
|
Green Impact Partners Inc
V:GIP
|
0.018x |
|
Wiable Corp
KQ:065530
|
-0.020x |
|
GROUP PAREF INH. EO 25
F:G5I
|
N/A |
|
Ginni Filaments Limited
NSE:GINNIFILA
|
0.156x |
Annual Cash Flow Conversion Efficiency for Actinium Pharmaceuticals Inc (2006–2025)
The table below shows the annual cash flow conversion efficiency of Actinium Pharmaceuticals Inc from 2006 to 2025. Review ATNM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.83 Million | $-24.58 Million | -3.138x | -210.78% |
| 2024-12-31 | $32.76 Million | $-33.07 Million | -1.010x | +22.41% |
| 2023-12-31 | $36.38 Million | $-47.34 Million | -1.301x | -1100.72% |
| 2022-12-31 | $66.48 Million | $8.64 Million | 0.130x | +145.83% |
| 2021-12-31 | $73.55 Million | $-20.87 Million | -0.284x | +19.52% |
| 2020-12-31 | $61.32 Million | $-21.62 Million | -0.353x | +90.73% |
| 2019-12-31 | $5.64 Million | $-21.46 Million | -3.802x | -62.89% |
| 2018-12-31 | $8.81 Million | $-20.57 Million | -2.334x | -48.06% |
| 2017-12-31 | $13.67 Million | $-21.55 Million | -1.577x | -36.57% |
| 2016-12-31 | $18.01 Million | $-20.79 Million | -1.154x | -36.80% |
| 2015-12-31 | $21.97 Million | $-18.54 Million | -0.844x | -111.31% |
| 2014-12-31 | $-1.92 Million | $-14.35 Million | 7.463x | +84.98% |
| 2013-12-31 | $-1.56 Million | $-6.29 Million | 4.035x | +188.68% |
| 2012-12-31 | $1.15 Million | $-5.21 Million | -4.550x | -71087.78% |
| 2011-12-31 | $-84.33K | $539.00 | -0.006x | +92.28% |
| 2010-12-31 | $-94.62K | $7.83K | -0.083x | -142.45% |
| 2009-12-31 | $-96.29K | $-18.78K | 0.195x | +3.32% |
| 2008-12-31 | $-73.96K | $-13.96K | 0.189x | -59.53% |
| 2007-12-31 | $-33.20K | $-15.49K | 0.467x | -38.81% |
| 2006-12-31 | $-18.40K | $-14.03K | 0.763x | -- |
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular… Read more